What is PT-141? A plain-English explainer

PT-141, bremelanotide, and Vyleesi are three names for the same molecule. PT-141 was the original Palatin Technologies research code. Bremelanotide is the international nonproprietary name. Vyleesi is the brand Cosette Pharmaceuticals sells in the United States. Online vendors and forum posts use all three interchangeably, so the first thing to nail down before reading anything else about this compound is that the name in front of you says nothing about whether what is being sold is a licensed medicine or a research vial.

What PT-141 actually does in the body

Bremelanotide is a cyclic heptapeptide, a seven-amino-acid chain closed into a loop by a lactam bridge, and an analogue of alpha-MSH (alpha-melanocyte-stimulating hormone), the pituitary signal that drives skin pigmentation and several brain effects. Its main targets are the MC3R and MC4R melanocortin receptors in the central nervous system, the same receptors involved in appetite regulation and, in this case, sexual-desire circuitry^[4]. The WHO classifies it under ATC code G02CX05, the gynecologicals category, reflecting that the approved indication sits firmly in women's sexual health^[5]. This central mechanism sets it apart from phosphodiesterase inhibitors such as sildenafil, which act peripherally on blood vessels. Bremelanotide also binds the MC1R receptor on skin melanocytes, which is why focal hyperpigmentation (darkening of skin on the face, gums or breasts) appears as a side effect in roughly one in a hundred patients who use the approved monthly schedule^[1].

The compound has an unusual history. Palatin Technologies tested it as an intranasal spray for erectile dysfunction in men and for female sexual dysfunction in the early 2000s. The FDA halted that programme in 2007 because clinical-trial subjects showed blood-pressure increases. Palatin then reformulated it as a lower-dose subcutaneous injection for a narrower indication, hypoactive sexual desire disorder (HSDD) in premenopausal women. That reformulated programme became Vyleesi, and the blood-pressure risk did not disappear: uncontrolled hypertension and known cardiovascular disease remain explicit contraindications on the current label^[1].

Where PT-141 is an approved medicine and where it is not

In the United States, the FDA approved Vyleesi (NDA 210557) on 21 June 2019 as a 1.75 mg subcutaneous injection for HSDD in premenopausal women, given at least 45 minutes before anticipated sexual activity, up to eight doses per month^[1]. That is the only lawful, quality-controlled route to bremelanotide in any jurisdiction: a US prescriber's prescription, dispensed from a regulated US pharmacy.

Outside the United States, the picture is sharply different. The EMA holds no marketing authorisation, EPAR, or referral for bremelanotide. The MHRA in the UK similarly has no authorised Vyleesi product. Lawful access in the EU, EEA and UK runs only through unlicensed-medicine or named-patient routes that a prescribing clinician must request and take responsibility for. General sale of bremelanotide to the public is not lawful in any of those regions. The 'PT-141' or 'bremelanotide' research vials sold by online vendors sit outside any pharmaceutical-grade quality framework and are not the same as the FDA-approved Vyleesi autoinjector. See the PT-141 regulation page for the country-by-country picture.

What the clinical evidence actually shows

The pivotal evidence comes from the RECONNECT phase 3 programme: two identically designed, randomised, double-blind, placebo-controlled trials (BMT-301 and BMT-302) published in Obstetrics and Gynecology in 2019 by Kingsberg and colleagues (n approximately 1,247 premenopausal women with HSDD)^[2]. Participants self-administered 1.75 mg bremelanotide or placebo subcutaneously on an as-needed basis over 24 weeks. The co-primary endpoints were change in the FSFI desire domain score and change in the FSDS-DAO item 13 distress measure. Both trials reported statistically significant improvements on both endpoints versus placebo. The effect sizes are modest, not large.

The most prominent adverse event is nausea: 40% of treated women reported it versus about 1% of women on placebo^[1]. Flushing occurred in roughly 20% and headache in about 11%. A 52-week open-label safety extension by Simon and colleagues found no new safety signals, with the nausea rate holding at around 40% and severe adverse events rare^[3]. Transient blood-pressure elevation peaks 2 to 4 hours after dosing and resolves within 12 hours in most patients, which is the pharmacological basis for the cardiovascular contraindications on the label.

What we do not yet know

The gaps in the evidence base are significant. We have no controlled trial data for bremelanotide in postmenopausal women, in men with sexual-desire complaints, or for erectile-dysfunction use, because the original male programme was halted in 2007 and has not been restarted in the same form. Off-label use in men and outside the approved on-demand HSDD schedule is common in community discussion, but the safety profile in those uses is not formally characterised. Whether focal hyperpigmentation fully resolves after stopping the drug in all affected patients is not fully answered. No sponsor has publicly disclosed plans to seek an EMA or MHRA marketing authorisation, so the non-US regulatory gap shows no signs of closing in the near term.

If you are considering whether bremelanotide is relevant to your situation, the questions worth bringing to a prescribing clinician are: whether the indication fits (premenopausal HSDD is the only supported use), whether cardiovascular or blood-pressure history rules it out, and what legal access looks like in your country. The full PT-141 peptide page covers mechanism, safety, dosing context, and regulatory status in more depth.